Efficacy of Dead Sea Peloid Gel in Chronic Endometritis

NCT ID: NCT02680275

Last Updated: 2016-02-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-07-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the effect of Dead Sea Peloid Gel in the treatment of Chronic Endometritis in women with reproductive disorders. Half of participants will receive Dead Sea Peloid Gel and antibiotics, while the other half will receive Placebo Gel and antibiotics.

Patients with reproductive disorders who visited Research Medical Center of Family Health Problems and Human Reproduction were recruited.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Dead Sea Peloid Gel achieves improvement of blood circulation and receptor sensitivity of endometrium.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Endometritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Doxycycline,Dead Sea Peloid Gel,placebo

1. Group -1 stage: Doxycycline 100mg 2 times per day 10 days; followed by Dead Sea Peloid Gel , 60 ml per day fo 12 days, intravaginally
2. Group -1 stage: Doxycycline 100mg 2 times per day 10 days; followed by placebo gel, 60 ml per day fo 12 days, intravaginally

Group Type EXPERIMENTAL

Dead Sea Peloid Gel

Intervention Type DRUG

intravaginally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dead Sea Peloid Gel

intravaginally

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Placebo Gel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women with miscarriage associated with chronic endometritis
* Women without mental disorders able to swallow tablets

Exclusion Criteria

* sexually transmitted diseases
* endometrium hyperplasia and/or polyps
* uterina fibroids
* endocrine disorders
* trombophilia
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Scientific Center for Family Health and Human Reproduction Problems, Russia

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Irina N. Danusevich

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marina A Darenskaya, MD

Role: STUDY_CHAIR

Scientific Center for Family Health and Human Reproduction Problems

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Scientific Center for Family Health and Human Reproduction Problems

Irkutsk, , Russia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Russia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

16

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Open-Label Extension Study to ZPE-202
NCT01961908 WITHDRAWN PHASE2